Physician profile
Paul Gonter
NPI 1295726933
$4,408.34
in general payments reported to CMS, 2019-2025
37 companies · $38.43 in 2025
The $38.43 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,004 · 2020: $578 · 2021: $570 · 2022: $1,164 · 2023: $53.28 · 2025: $38.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $91.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $91.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $611.37 | 2019-2022 | |
| Genentech USA, INC. | $479.67 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $454.17 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $421.13 | 2019-2022 | |
| Lilly USA, LLC | $295.50 | 2019-2022 | |
| Celgene Corporation | $294.33 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $248.37 | 2019-2022 | |
| Janssen Biotech, INC. | $186.61 | 2019-2023 | Darzalex, Imbruvica |
| Pfizer INC. | $134.59 | 2019-2022 | |
| Genzyme Corporation | $124.18 | 2019-2022 | |
| Abbvie INC. | $123.25 | 2019-2025 | |
| Seagen INC. | $113.86 | 2020-2022 | |
| Amgen INC. | $108.22 | 2019-2022 | |
| Astellas Pharma US INC | $77.60 | 2019-2020 | |
| Incyte Corporation | $64.65 | 2020-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $58.46 | 2021-2022 | |
| Gilead Sciences, INC. | $53.63 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $52.36 | 2019-2023 | Libtayo |
| Puma Biotechnology, INC. | $51.04 | 2019-2022 | |
| Exelixis INC. | $49.08 | 2019-2022 | |
| Myovant Sciences INC. | $48.89 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $42.99 | 2020-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $42.87 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.91 | 2020-2022 | |
| Tersera Therapeutics LLC | $29.17 | 2019 | |
| Innate Pharma, INC | $23.85 | 2020 | |
| Deciphera Pharmaceuticals INC. | $23.12 | 2022 | |
| Epizyme, INC. | $22.74 | 2022 | |
| Partner Therapeutics, INC. | $18.20 | 2019 | |
| Adc Therapeutics America, INC. | $18.08 | 2022 | |
| Array Biopharma INC | $17.81 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.48 | 2020 | |
| Kite Pharma, INC. | $16.40 | 2022 | |
| Karyopharm Therapeutics INC. | $14.83 | 2022 | |
| Emd Serono, INC. | $13.91 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $13.25 | 2019 | |
| Blueprint Medicines Corporation | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Gonter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.